# An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects

> **NCT01411800** · PHASE1 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** 250 mg capsule
- **DRUG:** 250 mg tablets

## Key facts

- **NCT ID:** NCT01411800
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2011-10
- **Final completion:** 2012-05
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2012-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01411800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01411800, "An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01411800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*